SCHEMBL2931146

SCHEMBL2931146

O=C(O)N1CCN(Cc2cc(Cl)ccc2O)CC1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
ALOX15 P16050 3/20 0.62
SMN1; SMN2 Q16637 3/20 0.62
KDM4E B2RXH2 3/20 0.62
TSHR P16473 3/20 0.62
MAPK1 P28482 2/20 0.62
BACE1 P56817 1/20 0.50
FAAH O00519 2/20 0.49
SLC2A1 P11166 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.47
LMNA P02545 4/20 0.46
HTT P42858 2/20 0.46
HPGD P15428 2/20 0.46
SLC22A1 O15245 1/20 0.46
USP2 O75604 1/20 0.46
HSP90AA1 P07900 1/20 0.46
CYP3A4 P08684 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795231 0.88 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL11154695 0.87 ALDH1A1 (0.61) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL2931356 0.82 ALDH1A1 (0.50) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL27693140 0.81 KMT2A (0.64) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL21802543 0.81 MGLL (0.54) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL4505464 0.80 VEGFA (0.61) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL27712884 0.80 TSHR (0.57) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL16636557 0.80 BACE1 (0.48) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL8388805 0.80 TSHR (0.66) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2
SCHEMBL2926486 0.79 ALDH1A1 (0.68) ALDH1A1MEN1KMT2AALOX15SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101448844-B Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE 2012-07-25 CN claimed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 EP claimed
CN-101448844-A Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE (CH) 2009-06-03 CN claimed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 EP claimed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO claimed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US claimed
CN-101448844-B Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE 2012-07-25 CN disclosed
EP-2027132-B1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-09-15 EP disclosed
CN-101448844-A Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists HOFFMANN LA ROCHE (CH) 2009-06-03 CN disclosed
EP-2027132-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-02-25 EP disclosed
WO-2007134958-A1 THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-11-29 WO disclosed
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives BRINKMAN JOHN A 2007-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270433-A1 Thiazolo-pyrimidine/pyridine urea derivatives ADORA2B, UTS2R, TBXA2R ALDH1A1 676/4885MEN1 4682/4885KMT2A 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.